APOBEC3G/F as one possible driving force for co-receptor switch of the human immunodeficiency virus-1

Medical Microbiology and Immunology

Volumn 201, Issue 1, 2012, Pages 7-16

  Heger, Eva ^a   Thielen, Alexander ^b   Gilles, Ramona ^a   Obermeier, Martin ^c   Lengauer, Thomas ^b   Kaiser, Rolf ^a   Trapp, Susanna ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^c Medizinisches Labor Dr Berg   (Germany)

Author keywords

APOBEC3F; APOBEC3G; Co receptor switch; HIV 1

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; GLYCOPROTEIN GP 120; APOBEC3F PROTEIN, HUMAN; APOBEC3G PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; HIV ENVELOPE PROTEIN GP120 (305 321); HIV ENVELOPE PROTEIN GP120 (305-321); PEPTIDE FRAGMENT;

AMINO ACID COMPOSITION; AMINO ACID SUBSTITUTION; ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; GENE MUTATION; GENE SWITCHING; GENETIC CODE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN MOTIF; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; UNINDEXED SEQUENCE; AMINO ACID SEQUENCE; CHEMISTRY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MUTATION; PATHOGENICITY; POLYMERASE CHAIN REACTION; VIROLOGY;

AMINO ACID SEQUENCE; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTORS, CCR5; RECEPTORS, CXCR4; SEQUENCE ALIGNMENT;

EID: 84860563312     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-011-0199-9     Document Type: Article

References (43)

1. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17:657-700
2. Sierra S, Kaiser R, Thielen A, Lengauer T (2007) Genotypic coreceptor analysis. Eur J Med Res 12(9):453-462
3. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73(12):10489-10502
4. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66(3):1354-1360
5. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG (2005) Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 191(6):866-872. doi:10.1086/428096
6. Bozzette SA, McCutchan JA, Spector SA, Wright B, Richman DD (1993) A cross-sectional comparison of persons with syncytium-and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 168(6):1374-1379
7. Alimonti JB, Ball TB, Fowke KR (2003) Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 84(Pt 7):1649-1661
8. Rosenberg YJ, Anderson AO, Pabst R (1998) HIV-induced decline in blood CD4/CD8 ratios: viral killing or altered lymphocyte trafficking? Immunol Today 19(1):10-17
9. Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J, O'Brien WA, Verdin E (1998) Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 395(6698):189-194
10. Zhang SY, Zhang Z, Fu JL, Kang FB, Xu XS, Nie WM, Zhou CB, Zhao M, Wang FS (2009) Progressive CD127 down-regulation correlates with increased apoptosis of CD8 T cells during chronic HIV-1 infection. Eur J Immunol 39(5):1425-1434
11. Delobel P, Nugeyre MT, Cazabat M, Pasquier C, Marchou B, Massip P, Barre-Sinoussi F, Israel N, Izopet J (2007) Populationbased sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 45(5):1572-1580
12. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J (1992) Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66(11):6777-6780
13. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R (2007) Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 25(12):1407-1410
14. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Saune K, Cuzin L, Marchou B, Massip P, Izopet J (2008) Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. Aids 22(14):F11-F16
15. Pathak VK, Temin HM (1990) Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proc Natl Acad Sci USA 87(16):6019-6023
16. Pathak VK, Temin HM (1990) Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: deletions and deletions with insertions. Proc Natl Acad Sci USA 87(16):6024-6028
17. Preston BD, Poiesz BJ, Loeb LA (1988) Fidelity of HIV-1 reverse transcriptase. Science 242(4882):1168-1171
18. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14(15):1392-1396
19. Bishop KN, Holmes RK, Sheehy AM, Malim MH (2004) APO-BEC-mediated editing of viral RNA. Science 305(5684):645
20. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418(6898):646-650
21. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 23(12):2451-2458
22. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113(6):803-809
23. Lecossier D, Bouchonnet F, Clavel F, Hance AJ (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300(5622):1112
24. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424(6944):99-103
25. Liddament MT, Brown WL, Schumacher AJ, Harris RS (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14(15):1385-1391
26. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S (2006) Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80(18):9259-9269
27. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 1(1):e6
28. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424(6944):94-98
29. Nowarski R, Britan-Rosich E, Shiloach T, Kotler M (2008) Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat Struct Mol Biol 15(10):1059-1066
30. Mulder LC, Harari A, Simon V (2008) Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci USA 105(14):5501-5506
31. Pillai SK, Wong JK, Barbour JD (2008) Turning up the volume on mutational pressure: is more of a good thing always better? (a case study of HIV-1 Vif and APOBEC3). Retrovirology 5:26
32. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A, Shaw GM, Hahn BH, Korber B, Seoighe C (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5(5):e1000414
33. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435(7038):108-114
34. Chelico L, Pham P, Calabrese P, Goodman MF (2006) APO-BEC3G DNA deaminase acts processively 3'-[5' on singlestranded DNA. Nat Struct Mol Biol 13(5):392-399
35. Pion M, Granelli-Piperno A, Mangeat B, Stalder R, Correa R, Steinman RM, Piguet V (2006) APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J Exp Med 203(13):2887-2893
36. Kreisberg JF, Yonemoto W, Greene WC (2006) Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med 203(4):865-870
37. Trapp S, Derby NR, Singer R, Shaw A, Williams VG, Turville SG, Bess JW Jr, Lifson JD, Robbiani M (2009) Double-stranded RNA analog poly (I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J Virol 83(2):884-895
38. Pido-Lopez J, Whittall T, Wang Y, Bergmeier LA, Babaahmady K, Singh M, Lehner T (2007) Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HSP70 up-regulates APOBEC3G expression in CD4(+) T cells and dendritic cells. J Immunol 178 (3):1671-1679
39. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22(22):4673-4680
40. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, Schuitemaker H (1992) Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66(5):3183-3187
41. Briggs DR, Tuttle DL, Sleasman JW, Goodenow MM (2000) Envelope V3 amino acid sequence predicts HIV-1 phenotype (coreceptor usage and tropism for macrophages). Aids 14(18):2937-2939
42. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E (2009) Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5(6):e1000495
43. Han Y, Wang X, Dang Y, Zheng YH (2008) APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. PLoS Pathog 4(7):e1000095